This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
The new glaucoma eye drop medication increases drainage through the eye’s conventional outflow pathways via a unique pharmacological action.
Although no studies prove a connection between specific foods and glaucoma, it’s safe to assume that your diet and your overall health can affect the disease.
If you are experiencing side effects from your glaucoma medications, learn what you can do to reduce or eliminate them.
Made possible by visionary donors, our latest research initiative targets the shared roots of conditions that occur when neurons deteriorate and die. …
The Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration will support creative collaboration by a team of four diversely talented young investigators.
The Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration is the inspiration of longtime GRF supporters Ted and Melza Barr.
What is neurodegeneration? And how will discoveries related to it affect people with glaucoma? …
Dr. John G. Flanagan discusses recent discoveries that could cure glaucoma based on key research accomplishments from 20 years of Catalyst for a Cure.
A study by US researchers compared levels of sight loss in patients with a new diagnosis of primary open-angle glaucoma.
Research paper summarizes the most important common elements that characterize progression in neurodegeneration and hope for new therapies to help patients with these devastating diseases.
MIGS founder announces the first-ever micro-invasive implantable device for standalone glaucoma treatment.
No strong evidence suggests excessive use of digital technology is a glaucoma risk factor. However, prolonged computer, tablet, cell phone, and other digital device use can lead to eye strain.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2023 all rights reserved.
